Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis

Basit Öğe Kaydı
dc.authoridTurgut, Seda/0000-0003-1700-0181
dc.authoridAr, Muhlis Cem/0000-0002-0332-9253
dc.authoridunlu, ayhan/0000-0001-6033-7148
dc.authoridozkan, tuba/0000-0002-0419-0214
dc.authorwosidTurgut, Seda/C-2468-2015
dc.authorwosidAr, Muhlis Cem/S-7530-2016
dc.authorwosidOzkan, Tuba/D-4490-2019
dc.authorwosidunlu, ayhan/Q-1843-2016
dc.contributor.authorCetin, Guven
dc.contributor.authorOzkan, Tuba
dc.contributor.authorTurgut, Seda
dc.contributor.authorCikrikcioglu, M. Ali
dc.contributor.authorAr, M. Cem
dc.contributor.authorAyer, Mesut
dc.contributor.authorUnlu, Ayhan
dc.date.accessioned2024-06-12T11:07:22Z
dc.date.available2024-06-12T11:07:22Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description.abstractEssential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia and thrombocytes are increased with abnormal functions. Discovery of the protein tyrosine kinase JAK2 V617F allele contributed to better understanding of the pathogenetic mechanisms of MPNs. Acquired single point mutation in the JAK2 V617F was determined approximately 50-60 % of patients with ET. In this study we aimed to investigate the relationship between JAK2 V617F gene mutation, hematologic, biochemical markers and the complications in the ET patients. A total of 268 patients diagnosed with ET and 219 of those studied for JAK2 gene mutation were followed at the hematology clinics of three major hospitals between 2008 and 2013 were screened retrospectively. Laboratory, clinical and hematologic parameters were compared for JAK2 V617F positive and JAK2 V617F negative patients with ET. 102 (46 %) patients were positive with the JAK2 V617F mutation. The complications were observed in 61 (28 %) patients and 38 (62 %) of them had JAK2 V617F mutation. The levels of white blood cells, neutrophil, basophil, red blood cells, hemoglobin, hematocrit, mean platelet volume, thrombocytes, eosinophil; urea, creatinine were significantly different in patients with the JAK2 V617F mutation (P < 0.05). Presence of the JAK2 V617F mutation supports the diagnosis of ET. It would be useful to investigate the JAK2 V617F mutation and the hematologic and biochemical markers at diagnosis with respect to consider the risk of developing complications and to take the precautions against these complications.en_US
dc.identifier.doi10.1007/s11033-014-3559-x
dc.identifier.endpage6742en_US
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue10en_US
dc.identifier.pmid25012914en_US
dc.identifier.scopus2-s2.0-84919400186en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage6737en_US
dc.identifier.urihttps://doi.org/10.1007/s11033-014-3559-x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21989
dc.identifier.volume41en_US
dc.identifier.wosWOS:000342440000045en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofMolecular Biology Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectJAK2 V617Fen_US
dc.subjectEssential Thrombocythemiaen_US
dc.subjectVascular Complicationsen_US
dc.subjectBiochemical Markersen_US
dc.subjectHematologic Markersen_US
dc.subjectTyrosine Kinase Jak2en_US
dc.subjectPolycythemia-Veraen_US
dc.subjectJak2(V617f)en_US
dc.subjectParametersen_US
dc.subjectGeneen_US
dc.titleEvaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu